- Home
- CBIO vs USCB Comparison
CBIO vs USCB Comparison
Compare CBIO & USCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- USCB
- Stock Information
- Founded
- CBIO 2003
- USCB 2002
- Country
- CBIO United States
- USCB United States
- Employees
- CBIO N/A
- USCB N/A
- Industry
- CBIO
- USCB Major Banks
- Sector
- CBIO
- USCB Finance
- Exchange
- CBIO Nasdaq
- USCB Nasdaq
- Market Cap
- CBIO 308.0M
- USCB 316.4M
- IPO Year
- CBIO N/A
- USCB 2021
- Fundamental
- Price
- CBIO $14.29
- USCB $17.34
- Analyst Decision
- CBIO Strong Buy
- USCB Buy
- Analyst Count
- CBIO 5
- USCB 3
- Target Price
- CBIO $25.60
- USCB $20.33
- AVG Volume (30 Days)
- CBIO 98.3K
- USCB 16.8K
- Earning Date
- CBIO 07-31-2025
- USCB 07-24-2025
- Dividend Yield
- CBIO N/A
- USCB 2.30%
- EPS Growth
- CBIO N/A
- USCB 67.08
- EPS
- CBIO N/A
- USCB 1.47
- Revenue
- CBIO N/A
- USCB $88,094,000.00
- Revenue This Year
- CBIO N/A
- USCB $26.38
- Revenue Next Year
- CBIO N/A
- USCB $4.39
- P/E Ratio
- CBIO N/A
- USCB $11.83
- Revenue Growth
- CBIO N/A
- USCB 32.06
- 52 Week Low
- CBIO $10.83
- USCB $13.85
- 52 Week High
- CBIO $21.40
- USCB $21.86
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- USCB 55.15
- Support Level
- CBIO $13.50
- USCB $17.10
- Resistance Level
- CBIO $16.00
- USCB $17.98
- Average True Range (ATR)
- CBIO 0.79
- USCB 0.52
- MACD
- CBIO 0.16
- USCB 0.06
- Stochastic Oscillator
- CBIO 39.68
- USCB 73.38
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.